Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour
详细信息 查看全文
- 作者：Andrew J. Wagnera ; b ; Andrew_Wagner@dfci.harvard.edu" class="auth_mail" title="E-mail the corresponding author ; Mark Agulnikc ; m-agulnik@northwestern.edu" class="auth_mail" title="E-mail the corresponding author ; Michael C. Heinrichd ; Heinrich@ohsu.edu" class="auth_mail" title="E-mail the corresponding author ; Daruka Mahadevane ; f ; dmahadevan@westclinic.com" class="auth_mail" title="E-mail the corresponding author ; Richard F. Riedelg ; Richard.riedel@duke.edu" class="auth_mail" title="E-mail the corresponding author ; Margaret von Mehrenh ; Margaret.vonmehren@fccc.edu" class="auth_mail" title="E-mail the corresponding author ; Jonathan Trenti ; j ; jtrent@med.miami.edu" class="auth_mail" title="E-mail the corresponding author ; George D. Demetria ; b ; george_demetri@dfci.harvard.edu" class="auth_mail" title="E-mail the corresponding author ; Christopher L. Corlessd ; corlessc@ohsu.edu" class="auth_mail" title="E-mail the corresponding author ; Murray Yulek ; Murray.Yule@astx.com" class="auth_mail" title="E-mail the corresponding author ; John F. Lyonsk ; John.lyons@astx.com" class="auth_mail" title="E-mail the corresponding author ; Aram Oganesianl ; Aram.oganesian@astx.com" class="auth_mail" title="E-mail the corresponding author ; Harold Keerl ; Harold.keer@astx.com" class="auth_mail" title="E-mail the corresponding author
- 关键词：Onalespib (AT13387) ; Non-ansamycin HSP90 inhibitor ; TKI-resistant GIST
- 刊名：European Journal of Cancer
- 出版年：2016
- 出版时间：July 2016
- 年：2016
- 卷：61
- 期：Complete
- 页码：94-101
- 全文大小：634 K
文摘
- •
This was a phase 1 clinical trial in patients with metastatic tyrosine kinase inhibitor (TKI)-resistant gastrointestinal stromal tumours (GIST).
- •
Treatment was a combination of onalespib (a heat-shock protein 90 inhibitor) and imatinib (a TKI).
- •
Treatment was well tolerated and toxicities consistent with known safety profiles.
- •
Disease control at 4 months was seen in five patients (19%); median progression-free survival was 112 d.
- •
One patient with PDGFRA-mutant GIST had a partial response for more than 376 d.